HOME >> BIOLOGY >> NEWS
Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs

oducts through the systematic application of genomics. CuraGen's fully integrated, Internet-based genomics technologies, services, and information systems are designed to rapidly generate comprehensive information about genes, human genetic variations, gene expression, biological pathways, and potential products that affect these pathways. CuraGen's strategic collaborators include Abgenix, Biogen, COR Therapeutics, Genentech, Glaxo Wellcome, Hoffmann-La Roche, and Pioneer Hi-Bred International. The Company employs over 300 people and is headquartered in New Haven, CT, with additional facilities in Branford, CT and Alachua, FL. Additional Company information is available at http://www.curagen.com. This release may contain forward-looking statements that are subject to certain risks and uncertainties, including the Company's ability to successfully enhance and develop its technologies. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the Company's early stage of development, technological uncertainty and product development risks, uncertainty of additional funding, reliance on research collaborations, competition, the Company's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights. Statements made in this press release about Abgenix's XenoMouse technology, product development activities and corporate partnerships other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual resu
'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
8-Dec-1999


Page: 1 2 3 4

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix initiates phase III clinical trial of graft versus host disease therapy
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Tufts University establishes $4 million dollar tissue engineering resource center
8. Corals can reestablish symbiosis with algae from their environments after bleaching
9. Researchers establish first molecular link between eating and aging
10. DFG establishes first German-Sino Research Training Group
11. New Woods Hole Center for Oceans and Human Health established

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... (PRWEB) , ... July 03, 2020 , ... ... proud to earn outstanding recognition and multiple awards for not only the products ... ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built by ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, ... the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga ... supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode ... in accelerated Point of Care Testing solutions (POCT). Check local listings for more info. ... at medical offices and are shipped to labs throughout the country. Results are then ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly regarded CDMO ... the purchase of greenfield for a new, expanded manufacturing facility. The site is ... in the initial acquisition, with an option to purchase an additional 21 acres ...
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... Texas (PRWEB) , ... July 29, 2020 , ... ... solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” The ... biopharmaceutical industry and around the globe, requiring fast track capacity to provide patients ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet ... to three different materials for use with CRM, neurostimulation, vascular, and related devices. ... to meet specific design requirements, performance, and cost criteria; especially where solid wire ...
Breaking Biology Technology:
Cached News: